Form 4: Baker Bros. Affiliates Report Director Stock Option Grant at vTv Therapeutics

Entities affiliated with Baker Bros. Advisors LP, including key principals, have reported the grant of 4,000 non-qualified stock options to Dr. Raymond Cheong, a director of vTv Therapeutics Inc., as part of his compensation.

Summary

• Dr. Raymond Cheong, a director of vTv Therapeutics Inc. (VTVT) and a full-time employee of Baker Bros. Advisors LP, was granted 4,000 non-qualified stock options.
• The stock options have a strike price of $16.59 per share.
• These options were granted on June 10, 2025, under the Issuer's 2024 Equity Incentive Plan.
• The options vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders, contingent on Dr. Cheong's continued service on the board or an earlier change in control.
• The stock options are exercisable into Class A common stock and expire on June 10, 2035.
• Baker Bros. Advisors LP, 667, L.P., Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker are reporting persons due to their indirect pecuniary interest in these options, as Dr. Cheong serves as a representative of their interests on the board.
• Pursuant to Baker Bros. Advisors' policies, Dr. Cheong does not have a direct right to these securities; instead, the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) are entitled to an indirect proportionate pecuniary interest.

Sentiment

Score: 6

Explanation: The document reports a routine director compensation grant, which is a neutral event. It reflects ongoing governance and incentive alignment but does not indicate significant positive or negative operational or financial news.

Positives

• The grant of stock options to a director aligns director incentives with shareholder value creation, as the options gain value if the stock price rises above the $16.59 strike price.
• The vesting schedule encourages Dr. Cheong's continued service on the board, providing stability in governance.

Negatives

• The options are non-qualified, which may have different tax implications for the recipient compared to incentive stock options, though this is standard for director compensation.
• The strike price of $16.59 is a specific value, and if the stock price remains below this, the options would hold no intrinsic value.

Future Outlook

The document does not provide a general future outlook for the company, but the stock option grant's vesting schedule and expiration date imply a long-term incentive for the director.

Management Comments

• Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, is a director of vTv Therapeutics Inc. By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.
• Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

Industry Context

This Form 4 filing details a standard director compensation grant within the biotechnology/pharmaceutical industry, where equity incentives are common to align director interests with long-term company performance. Baker Bros. Advisors is a prominent investment firm specializing in life sciences, and their representation on the board of vTv Therapeutics Inc. is consistent with their investment strategy in the sector.

Corporate Governance

Related Party Transactions

• The grant of 4,000 non-qualified stock options to Dr. Raymond Cheong, a director of vTv Therapeutics Inc. and an employee of Baker Bros. Advisors LP, constitutes a related party transaction.
• Entities affiliated with Baker Bros. Advisors LP, including 667, L.P. and Baker Brothers Life Sciences, L.P., and principals Felix J. Baker and Julian C. Baker, have an indirect pecuniary interest in these options, further highlighting the related party nature of the transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's interests with those of shareholders by incentivizing an increase in the company's stock price. However, it also represents potential dilution upon exercise.
• Employees: Dr. Cheong, as an employee of Baker Bros. Advisors LP, receives this compensation in his capacity as a director of vTv Therapeutics, which is distinct from general employee compensation.

Next Steps

• The stock options are subject to vesting on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of the Issuer's shareholders.
• The options will expire on June 10, 2035, if not exercised.

Key Dates

Keywords

vTv Therapeutics, VTVT, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Incentive Plan, Baker Bros. Advisors, Biotechnology, Pharmaceuticals